GLOW Peptide Dosage Calculator and Protocol Guide

GLOW Peptide Dosage

Each GLOW dose is 2.8 mg per injection and contains 2 mg GHK-Cu + 400 mcg BPC-157 + 400 mcg of Thymosin Beta-4. A 70 mg GLOW vial reconstituted with 2.5 mL BAC water (28 mg/mL) results in a dose of 10 syringe units. The 12-week GLOW protocol keeps that dose constant: 2.8 mg daily in weeks 1–4, 2.8 mg 5x per week in weeks 5–8, and 2.8 mg 2-3x per week for maintenance in weeks 9–12.

What’s in a GLOW Vial?

A standard 70 mg GLOW vial contains three peptides in fixed mass ratios: 50 mg GHK-Cu, 10 mg BPC-157, and 10 mg full-length TB-4.

Skin repair slows with age across several connected systems: collagen genes fire less, capillary supply thins, and repair cells lose coordination. By design, GLOW assigns one peptide to address each bottleneck.

The GLOW peptide blend contains three peptides in a fixed 50/10/10 mg ratio:

• GHK-Cu — Builds new collagen and clears damaged tissue at the same time.¹ Most collagen interventions only do the first; this is what makes GLOW a skincare stack.
• BPC-157 — Sprouts new small blood vessels into the dermal repair area (angiogenic signaling²). Without that capillary supply, GHK-Cu has the signal but no nutrient delivery to the treatment site.
• TB-4 (full-length thymosin β4, 43 aa) — Moves repair cells into position and biases healing toward functional tissue rather than rope-like scarring.³ ⁴

GLOW uses the full-length TB-4 parent, not the shorter TB-500 fragment; the two are blurred on labels routinely.⁵ Confirm what sequence is in the vial by reviewing third-party lab reports.

GLOW coordinates three jobs that skin remodeling needs at the same time. GHK-Cu changes the repair instructions, BPC-157 supports the capillary supply, and TB-4 gives repair cells the internal structure they need to move through tissue. The blend has not been tested as a complete formulation; its rationale comes from the complementary mechanisms of the three peptides.

GHK-Cu: collagen and structure

What it is

GHK-Cu is a three-amino-acid peptide bound to copper. It carries copper into the repair processes that build and organize the skin’s structural matrix.

How it works

GHK-Cu changes which repair instructions skin cells follow, increasing collagen, elastin, and antioxidant production while helping clear damaged tissue. Its copper also supports lysyl oxidase, the enzyme that cross-links new collagen fibers and gives the matrix strength (gene regulation, tissue clearing, and collagen cross-linking¹).

Lysyl oxidase only works once copper is loaded onto it inside the cell, and GHK-Cu supplies that copper: a 2025 delivery study measured copper accumulating in the right compartment and lysyl oxidase activity rising to 1.78 times control.⁹ A second 2025 group found the same copper-handoff behavior from a different GHK-based molecule.¹⁰ That is the chain the mechanism predicts, measured end to end — copper delivered, the cross-linking enzyme switched on, matrix built and locked together.

More is not better. Matrix synthesis peaks at low concentrations and falls back toward baseline as the dose climbs, so the dose-response curve has a hump rather than a slope.¹¹

Role in GLOW

GHK-Cu addresses both sides of skin remodeling: removing damaged matrix and building its replacement. It is the main rebuilding signal in GLOW, while BPC-157 supports the blood supply and TB-4 helps position repair cells.

Evidence

GHK-Cu is associated with regulation across more than 4,000 genes, including collagen synthesis, antioxidant defense, wound healing, inflammation, and tissue breakdown. Circulating levels decline with age, from roughly 200 ng/mL at age 20 to about 80 ng/mL by 60.¹

Elastin is what gives skin its snap-back, and two labs have measured GHK-Cu raising it in human skin cells. A 2026 study titrated the copper peptide across 1–50 ppm and found elastin secretion peaking around 150% of control at 5 ppm; in cells that had been UV-burned first, the peptide raised both elastin gene activity and secreted elastin protein.¹² An earlier study found the same direction at nanomolar concentrations.¹

Six human topical studies exist. Five report improvement — skin density and thickness, wrinkle depth, elasticity, and in one 12-week comparison, more collagen improvement than either vitamin C or tretinoin. One found nothing: a trial in skin freshly resurfaced by a CO2 laser, where blinded evaluators saw no difference against the control regimen.¹³

Every one of those studies put GHK-Cu on the skin. Injecting it has never been tested in a human trial, which is not the same as nobody having done it — injectable GHK-Cu is widely self-administered.

One injectable exposure is documented: a 50-year-old woman self-injected 132 mg after a reconstitution error, 66 times her intended 2 mg, and was asymptomatic when she presented.¹⁴ No copper, ceruloplasmin, kidney, or liver testing was reported. The case shows that one large exposure produced no acute symptoms and nothing further — an informative datapoint on safety.

Copper exposure can be calculated: 2 mg of GHK-Cu carries about 316 mcg of elemental copper — daily dosing of GLOW adds roughly 0.3 mg per day on top of what food supplies.¹⁵ Injected copper also bypasses the gut and liver, where dietary copper intake is regulated. The two routes are not interchangeable. To date, no published reference has measured serum copper, ceruloplasmin, or copper balance in a person using injectable GHK-Cu.

BPC-157: blood supply

What it is

BPC-157 is a synthetic 15-amino-acid peptide modeled from a protective protein fragment found in gastric juice. Its role in GLOW is to support the blood supply behind tissue repair rather than build collagen directly.

How it works

BPC-157 signals blood-vessel cells to relax existing vessels, move into damaged tissue, and form new capillaries. In tendon repair cells, it also increased the number of places where growth hormone can attach; it made the cells more responsive when growth hormone was present without activating the signal on its own (new blood vessel formation²).

Role in GLOW

Active skin remodeling needs oxygen, nutrients, and a route for repair cells to reach the area. BPC-157 supports that supply layer so oxygen and nutrients can reach the tissue while GHK-Cu and TB-4 do their repair work.

Evidence

More than 100 pre-clinical repair studies support BPC-157's blood-vessel signaling and repair-cell effects. The human evidence is limited but crucially provides a baseline safety assessment:

• A randomized double-blind placebo-controlled Phase 2 enema trial in ulcerative colitis with 53 participants, published only as a meeting abstract. Its confidence interval spans zero and is wider than the point estimate, so it was too small to detect the difference it observed — uninformative rather than null.
• An intra-articular knee series with 16 patients analyzed. Fourteen improved, and 7 of 12 reported durable improvement beyond six months by telephone follow-up.
• A hamstring registration with estimated enrollment and no disclosed dose. It remains provenance-flagged and registered-unverified.

Across the completed studies and case series, no major adverse events were reported. No published research has directly studied BPC-157's ability to build new capillaries in skin or improve a GLOW outcome.² The skincare rationale comes from established mechanisms in pre-clinical research. Human evidence for GLOW skincare effectiveness is limited to individual self-reports — anecdotal signals, not controlled experiments with measured endpoints.

TB-4: cell migration

What it is

TB-4 is a naturally occurring 43-amino-acid peptide involved in cell movement and tissue repair. It is not the same molecule as TB-500, the shorter 17–23 fragment, even when product labels use the names interchangeably.⁵

How it works

Repair cells move by building and releasing an internal scaffold made from actin. TB-4 holds loose actin in reserve so the scaffold can be assembled where it is needed. TB-4 can also release Ac-SDKP, a smaller peptide studied for anti-scarring and anti-inflammatory effects (actin sequestration and Ac-SDKP release³ ⁴).

Role in GLOW

TB-4 supports the movement of repair cells through damaged tissue and the organization of the rebuilding process. Its role complements GHK-Cu: TB-4 helps position the repair cells, while GHK-Cu handles more of the matrix-building work.

Evidence

Full-length TB-4 has human clinical research across corneal, cardiac, and wound-repair programs, including clean Phase 1 safety data, plus dermal wound-healing models. Those studies support the broader repair mechanism. They do not establish the efficacy of a 400 mcg SubQ dose in GLOW, and their findings cannot be assigned to a TB-500 fragment vial.³ ⁴ ⁵ ⁶

Regulatory Status

The July 2026 compounding review covered BPC-157 and TB-500, not the premixed GLOW blend or the TB-4 used in GLOW.

BPC-157

• On 23 July 2026, PCAC voted to recommend adding BPC-157 to the 503A Bulks List.
• BPC-157 was removed from Category 2 on 22 April 2026 after its nominator withdrew it.
• BPC-157 is no longer in Category 2; its final 503A listing remains pending.

TB-4

• The July 23, 2026 PCAC recommendation covered TB-500, not the TB-4 used in GLOW.
• TB-500 is a fragment of TB-4, the 43-amino-acid parent peptide. TB-4 has substantially more human safety data than the fragment.
• Vendors often use the TB-4 and TB-500 names interchangeably, or confuse the two.

BPC-157 and TB-500 are recommended for listing. Their final 503A status remains pending.

GHK-Cu

• Injectable GHK-Cu was moved to Category 2 in September 2023.
• GHK-Cu will return to PCAC for a vote before the end of February 2027.
• HHS has announced that GHK-Cu is expected to return to Category 1, which would restore compounding access for injectable formulations.⁸

GLOW Dosing Protocol

The standard protocol for GLOW is 2.8 mg per injection: 2 mg GHK-Cu with 400 mcg each of BPC-157 and TB-4.

• Reconstitute a GLOW-70 vial by adding 2.5 mL of BAC water
• That delivers a concentration of 28 mg/mL
• The resulting dose per injection: 2.8 mg ÷ 28 mg/mL = 0.1 mL or 10 units on a U-100 insulin syringe

Each 70 mg vial of GLOW supplies 25 daily doses and remains within the 28-day refrigerated-use window. Morning and evening both work; consistency across scheduled dosing days matters more than the hour of injection.

Note: GLOW has no trial-established dose that combines the three compounds; the dose is derived by combining the ranges of each individual peptide.

12-week GLOW protocol for skincare

The GLOW protocol runs for 12 weeks, split into three phases, followed by 4–8 weeks off. The 2.8 mg dose remains fixed while frequency decreases from daily -> 5x per week -> 2-3x per week.

No controlled trial has tested this schedule or established when skin changes should appear — and while reports on public forums are extensive, each individual may respond differently. In addition, the Supporting Factors — such as sleep and hydration — will materially affect results.

Phase 1: Activation (Weeks 1–4)

Dose: Daily

• GHK-Cu activates collagen production while its copper component enables proper structural cross-linking¹
• BPC-157 builds the network of small blood vessels needed to feed active tissue²
• TB-4 mobilizes and organizes repair cells³

Expected: Skin hydration improves, tone evens, and texture softens.

Baseline photos. Progress on skin is gradual; week-0 photos are the only reliable progress marker at week 6.

Phase 2: Remodeling (Weeks 5–8)

Dose: 5x per week

Same per-injection amounts. All compounds at peak coordinated activity.

• GHK-Cu drives maximum collagen production — structural proteins, elastin for bounce-back, and the water-binding molecules that keep skin hydrated from within¹
• BPC-157 maintains blood flow to active tissue²
• TB-4 coordinates efficient cell organization³

Expected: Fine lines soften, elasticity improves, visible glow returns, and skin thickness increases.

Progress photos. Measure week 6 against the week-0 baseline.

Phase 3: Maintenance (Weeks 9–12)

Dose: 2-3x per week

Pulsed administration keeps the repair signal present without turning the protocol into constant stimulation.

• Signal sensitivity — pulsed dosing is the conservative way to avoid blunting the response over time.
• Integration time — newly synthesized collagen needs 48–72 hours between pulses to organize and cross-link.
• Maintenance fit — long-running protocols usually work better as a cadence than as daily pressure forever.

Take a 4–8-week break between GLOW cycles; none of the compounds have been studied for continuous use.

Progress photos. Compare week 12 with the week-0 baseline and week 6.

The full schedule uses 56–60 injections, and each 70 mg GLOW vial contains 25 standard doses by mass. CDC summarizes USP guidance: date an opened multi-dose vial at first puncture and discard it within 28 days.⁷ The dose count and 28-day window together require three vials for the 12-week protocol.

Cycled topical actives such as retinoids, vitamin C, and niacinamide are sometimes paired with GLOW during the active weeks. GLOW targets dermal structure; the topicals target surface turnover and pigmentation.

Phasing and lifestyle inputs are covered in Supporting Factors below.

Conditional Add-Ons

NAD+ is the primary metabolic add-on considered for GLOW. It may be relevant when remodeling occurs under metabolic strain — GLP-1 use, caloric deficit, or chronic fatigue. The add-on protocol for NAD+ is 100–200 mg IM, 2-3x per week. NAD+ requires a different syringe and site because its acidity can degrade peptides on contact.

GLOW alone handles standard skin quality. The remaining layers are conditional — added only when a specific bottleneck shows up, not by default:

Topical GHK-Cu / AHK-Cu + minoxidil. Fits hair shedding during GLP-1 use or aggressive dieting. Either copper peptide alone works if availability or tolerance is a constraint. The underlying deficit matters too — hair follicles need direct scalp exposure plus enough protein and calories to grow.

MT-I (afamelanotide), not MT-II. Fits when pigment with photoprotection sits alongside skin-quality goals. MT-II’s central nervous-system side effects make it the wrong default.

Sermorelin / Tesamorelin / Ipamorelin. Only for the growth-hormone-deficiency pattern (poor sleep + low recovery). Not a default layer.

KLOW is the better fit when inflammation emerges or baseline reactivity is the limit. Continuous standalone KPV alongside GLOW produces the same four-peptide composition with more handling.

Tell FoxAI your situation and it builds the right stack→

Phenotype Considerations

Perimenopausal users. Estrogen-driven collagen decline accelerates during perimenopause, and substrate is typically already more depleted at baseline. The full 12-week, three-phase cycle remains the baseline rather than compressing the protocol into eight weeks; activation remains weeks 1–4.

Recent surgery. The convention defers at least two weeks after major surgery. Excessive angiogenesis during early surgical healing can complicate scar formation.

GLP-1 users / aggressive cutting. Rapid weight loss outpaces the skin’s ability to remodel, and substrate availability tightens. NAD+ from the start fits here, with the topical hair overlay where shedding emerges.

Supporting Factors

These inputs support tissue synthesis, collagen cross-linking, matrix hydration, copper balance, and overnight repair:

Optional adjuncts: red-light therapy (630–670 nm) for 10–20 minutes daily, and microneedling every three to four weeks during Phase 2.

Safety & Considerations

Active cancer or cancer history. GLOW is excluded during active cancer treatment. The blood-vessel signaling associated with GHK-Cu, BPC-157, and TB-4 creates a theoretical concern, not a measured human tumor risk.

Five years after treatment or remission is used as a conservative review window — any use within that window requires explicit clearance and ongoing supervision from the clinician managing the cancer history; after five years, medical review still applies when recurrence risk or active surveillance remains relevant.

Wilson’s disease or copper overload. GHK-Cu delivers 50 mg copper-bound peptide per vial; it is contraindicated in anyone with copper-handling disorders.

Pregnancy or breastfeeding. No safety data for any of the three peptides during pregnancy.

WADA-tested athletes. TB-4 is on the prohibited list; GLOW is not usable in competition.

Reactive or rosacea-prone skin. GLOW does not address inflammatory tone; KLOW is the better tool for these cases.

Conventional alternatives include topical retinoids and in-office collagen-induction procedures. They act through different tissue layers and carry different downtime and cost profiles.

Reconstituting GLOW

All three peptides are premixed in a GLOW vial — any draw calculation uses the vial’s full 70 mg at the fixed 5:1:1 ratio:

V_draw = D_GLOW × V_waterM_vial

GLOW vials can vary in the exact amount of each compound included. Even if the vial is labeled as 70 mg with the 5:1:1 ratio, it is advisable to check the vendor CoA (Certificate of Analysis) to validate the exact mix.

A vial that differs from the label makes the draw math more complicated and, by extension, error-prone. The FoxAI GLOW Dosage Calculator above takes any vial mix and target dose and solves the BAC water volume that lands on a clean syringe draw.

Example: 2.8 mg of GLOW in a 0.1 mL, or 10-unit, draw.

V_water = 0.1 mL × 70 mg2.8 mg = 2.5 mL BAC water

Follow the visual reconstitution guide for a step-by-step walkthrough on reconstituting, handling, and storing a GLOW vial.

FAQ

Related Topics

• KLOW Dosing Calculator — The 4-peptide variant with KPV for reactive or post-procedure skin
• Injury Recovery Peptide Protocol — Five-compound structural repair framework including NAD+ metabolic support
• BPC-157 + TB-500 Wolverine Stack — Simpler injury recovery stack centered on the two core repair peptides
• BPC-157 Guide — Standalone dosing, pharmacokinetics, oral vs injectable
• TB-500 / TB-4 Guide — Fragment vs full-length, CoA verification, threshold-saturation mechanism
• GHK-Cu Guide — Copper peptide mechanism for skin and matrix quality
• NAD+ Guide — Cellular energy support for intensive repair cycles
• Peptide Reconstitution Guide — General bacteriostatic water and syringe handling
• Where to Inject GLOW Peptide — Near-injury vs systemic injection routing

References

¹ GHK-Cu tissue-organization signaling and copper-peptide complex — TGF-β/Smad matrix organization, lysyl oxidase cross-linking, SOD/catalase antioxidant expression, copper coordination chemistry, 4,000+ gene modulation: PubMed 29986520; age-related plasma decline (roughly 200 ng/mL at age 20 to about 80 ng/mL by 60): Pickart L, Margolina A. Int J Mol Sci 2018. DOI: 10.3390/ijms19071987

² BPC-157 angiogenic signaling — VEGFR2-Akt-eNOS activation, nitric oxide bioavailability, FAK-paxillin cell-anchoring cascade, anti-cytokine modulation: PMC8275860

³ TB-4 / TB-500 G-actin sequestration and threshold-saturation mechanism — actin-monomer binding, cytoskeletal mobilization for cell migration, mass-action pharmacodynamics requiring bolus dosing: PubMed 12581423

⁴ TB-4 Ac-SDKP anti-fibrotic fragment — N-terminal tetrapeptide (fragment 1–4) released by meprin-α and POP processing; suppresses TGF-β-driven fibrosis and cardiac/renal remodeling: PMC4889319; fragment-specific activity review: PMC8724243

⁵ TB-4 / TB-500 product mislabeling — documented bidirectional mislabeling between full-length TB-4 (43 aa) and the TB-500 fragment (residues 17–23) in marketed peptide products: Esposito M et al. Drug Test Anal 2012. PubMed 22962027

⁶ TB-4 Phase 1 human safety — first-in-human randomized, double-blind, single- and multiple-dose Phase 1 of recombinant human thymosin β4 in healthy volunteers, no serious adverse events: PubMed 34346165; intravenous TB-4 Phase 1 safety and pharmacokinetics, no dose-limiting or serious adverse events (Ann N Y Acad Sci 2010;1194:223–229): NCT00743769

⁷ Centers for Disease Control and Prevention. Preventing Unsafe Injection Practices: multi-dose vial handling and beyond-use guidance. CDC injection-safety guidance

⁸ On February 27, 2026, HHS Secretary Kennedy announced that GHK-Cu is among approximately 14 peptides expected to return to Category 1.

⁹ GHK-Cu as copper source for lysyl oxidase activation — Golgi-targeted delivery via ATOX1/ATP7A; LOX activity 1.78x control in vitro, rabbit fascia defect model. GHK-Cu supplied the copper within a scaffold that also delivered ATOX1 mRNA, so the LOX increase reflects the combined system: Wang et al. J Control Release 2025. PubMed 41371501

¹⁰ Copper-handoff behavior of GHK conjugates — hyaluronan-GHK glycoconjugates act as copper ionophores, raising intracellular copper via the CCS and Atox-1 chaperones with downstream BDNF, BMP-2, and VEGF expression: Naletova et al. Antioxidants 2025. PubMed 41462712

¹¹ Biphasic dose-response — GHK-Cu stimulated sulfated glycosaminoglycan synthesis in normal human fibroblasts with maximal effect at 10^-9 to 10^-8 M; at higher concentrations the synthesis rate returned progressively to control: Wegrowski et al. Life Sci 1992. PubMed 1522753

¹² Elastin measurement — Copper Tripeptide-1 across 1-50 ppm in Hs68 human dermal fibroblasts raised secreted elastin dose-dependently to approximately 150% of control at 5 ppm (ELISA); after UV-B 20 mJ/cm2, it raised ELN gene expression and secreted elastin protein. Authors note no elasticity or desmosine measurement, and the ex vivo skin arm tested a three-compound combination rather than the peptide alone. Industry lab (LG Household and Health Care): Ye et al. Curr Issues Mol Biol 2026. PMC13204052

¹³ CO2 laser-resurfaced skin — 13 patients completed; blinded evaluators and computer analysis found no difference in erythema resolution, wrinkle improvement, or overall skin quality between the GHK-Cu regimen and control: Miller et al. Arch Facial Plast Surg 2006. PubMed 16847171

¹⁴ Injectable overdose case — 50-year-old female, 132 mg self-injected against an intended 2 mg (66-fold reconstitution error), asymptomatic at presentation, managed with home monitoring and outpatient follow-up. No serum copper, ceruloplasmin, renal, or hepatic values were reported and no timepoints were given. Source is a clinical toxicology teaching bulletin (Clinical Pharmacology and Toxicology Pearl of the Week, Alberta, 2026), not a peer-reviewed case report: Yarema et al. 2026.

¹⁵ Copper content per dose — the canonical 1:1 neutral complex [Cu(GHK-2H)], C14H22N6O4Cu, MW 401.91, is 15.81% copper by mass, giving 158.1 mcg copper per mg of GHK-Cu; a 2 mg dose therefore carries 316 mcg. Vendor material at other stoichiometries carries less: the 2:1 (GHK)2-Cu form is 8.54% copper. Computed from IUPAC 2021 atomic masses.